Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Liabilities and Shareholders Equity (2016 - 2025)

Palisade Bio has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $134.3 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 1134.78% to $134.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $156.2 million through Dec 2025, up 241.45% year-over-year, with the annual reading at $134.3 million for FY2025, 1134.78% up from the prior year.
  • Liabilities and Shareholders Equity was $134.3 million for Q4 2025 at Palisade Bio, up from $7.0 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $134.3 million in Q4 2025 and troughed at $6.7 million in Q2 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $12.8 million (2024), against an average of $18.4 million.
  • The largest YoY upside for Liabilities and Shareholders Equity was 1134.78% in 2025 against a maximum downside of 48.2% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $12.5 million in 2021, then increased by 25.98% to $15.8 million in 2022, then decreased by 10.85% to $14.1 million in 2023, then dropped by 22.57% to $10.9 million in 2024, then soared by 1134.78% to $134.3 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Liabilities and Shareholders Equity are $134.3 million (Q4 2025), $7.0 million (Q3 2025), and $6.7 million (Q2 2025).